Lauren L Levy1, Jennifer Urban1, Brett A King2. 1. Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut. 2. Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut. Electronic address: Brett.King@yale.edu.
Abstract
BACKGROUND: Treatment of moderate to severe atopic dermatitis (AD) is often inadequate. OBJECTIVE: We sought to evaluate the efficacy of the oral Janus kinase inhibitor tofacitinib citrate in the treatment of moderate to severe AD. METHODS: Six consecutive patients with moderate to severe AD who had failed standard treatment were treated with tofacitinib citrate. Response to treatment was assessed using the Scoring of AD index. RESULTS: Decreased body surface area involvement of dermatitis and decreased erythema, edema/papulation, lichenification, and excoriation were observed in all patients. The Scoring of AD index decreased by 66.6% from 36.5 to 12.2 (P < .05) during 8 to 29 weeks of treatment. There were no adverse events. LIMITATIONS: Small sample size, lack of placebo control group, and the possibility of bias are limitations. CONCLUSION: The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD. Published by Elsevier Inc.
BACKGROUND: Treatment of moderate to severe atopic dermatitis (AD) is often inadequate. OBJECTIVE: We sought to evaluate the efficacy of the oral Janus kinase inhibitor tofacitinib citrate in the treatment of moderate to severe AD. METHODS: Six consecutive patients with moderate to severe AD who had failed standard treatment were treated with tofacitinib citrate. Response to treatment was assessed using the Scoring of AD index. RESULTS: Decreased body surface area involvement of dermatitis and decreased erythema, edema/papulation, lichenification, and excoriation were observed in all patients. The Scoring of AD index decreased by 66.6% from 36.5 to 12.2 (P < .05) during 8 to 29 weeks of treatment. There were no adverse events. LIMITATIONS: Small sample size, lack of placebo control group, and the possibility of bias are limitations. CONCLUSION: The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD. Published by Elsevier Inc.
Authors: George Martin; Bruce E Strober; Craig L Leonardi; Joel M Gelfand; Andrew Blauvelt; Arthur Kavanaugh; Linda Stein Gold; Brian Berman; Ted Rosen; Eggert Stockfleth Journal: J Clin Aesthet Dermatol Date: 2016-09-01
Authors: Andreas Ritzén; Morten D Sørensen; Kevin N Dack; Daniel R Greve; Anders Jerre; Martin A Carnerup; Klaus A Rytved; Jesper Bagger-Bahnsen Journal: ACS Med Chem Lett Date: 2016-04-14 Impact factor: 4.345